A low-cost topical immunotherapy formulation suitable for treating cervical cancer in low and middle income countries and low-resource settings in the U.S.

一种低成本局部免疫治疗制剂,适用于低收入和中等收入国家以及美国资源匮乏地区的宫颈癌治疗。

基本信息

  • 批准号:
    10252242
  • 负责人:
  • 金额:
    $ 40万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-01 至 2023-04-30
  • 项目状态:
    已结题

项目摘要

The goal of this project is to deliver an affordable immunotherapy to treat advanced cervical cancer in low- and middle-income countries (LMICs) and low-resource settings in the U.S. A longer-term goal is to treat earlier stages of cervical dysplasia and assess immunity to the causative agent, human papillomavirus (HPV). The heavy burden of suffering and death from cervical cancer disproportionately falls on women in resource poor settings. Overcoming barriers to treatment, i.e. lack of infrastructure, trained specialists, specialized equipment, cold chain, and financial resources, requires a paradigm shift in the approach to treatment that can be achieved by the innovative immunotherapeutic agent proposed here. IFx-Hu2.1 (SN63/016,700) is a cream-based therapeutic immunomodulator that will be optimized for stability and performance. Our IFx-Hu2 family contains a plasmid DNA (pDNA) bulk drug substance, which can be produced for a fraction of the cost of current immunotherapies. The pDNA encodes a complex bacterial antigen, Emm55. When expressed on the tumor cell surface, Emm55 attracts antigen presenting cells and other cells of the innate immune response. Non-self-epitopes such as tumor and HPV antigens are then exposed in such a way as to set up multi-antigenic cellular and humoral adaptive immune responses. Emm55-based therapies induce personalized, multivalent, systemic, and sustained immune responses and have the potential to treat a broad range of cancers through enhanced tumor recognition, immune activation and epitope spreading. Intralesional injection of IFx-Hu2.0 has an established safety profile in multiple animal studies and is currently being tested in Phase 1 human clinical trials for cutaneous melanoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma. Our preliminary clinical data corroborate pre-clinical observations, showing the activation of T- and B-cell immune responses and tumor reduction, with no short or long-term adverse effects. We propose to optimize the IFx-Hu2.1 formulation for temperature stability using established methods and models. In vitro evaluation, to include standard quality control methods and a human vaginal epithelium carcinoma model, will be followed by in vivo uptake, expression, and disease progression studies in a mouse model of cervical cancer. Room temperature storage and self-administration will circumvent onerous clinic visits, improve prognosis and preserve fertility. IFx-Hu2.1 cream formulation will provide a non-toxic cancer therapeutic treatment with minimal supportive care requirements, featuring unique delivery, and high applicability/impact to underserved populations. The data obtained by completing these studies will position Morphogenesis, Inc. to submit an Investigational New Drug application to conduct a clinical trial for women in a local community hospital (low-resource setting) and in South Africa (LMIC). These trials will be the objective of an SBIR Phase 2 proposal.
该项目的目标是提供一种负担得起的免疫疗法,以治疗晚期宫颈癌, 一个长期的目标是更早地治疗 子宫颈发育不良的分期和评估对病原体人乳头瘤病毒(HPV)的免疫力。的 宫颈癌造成的痛苦和死亡的沉重负担不成比例地福尔斯在资源贫乏的妇女身上 设置.克服治疗障碍,即缺乏基础设施、训练有素的专家、专门设备, 冷链和财政资源,需要在治疗方法上实现范式转变, 由这里提出的创新免疫剂。 IFx-Hu 2.1(SN 63/016,700)是一种乳膏型治疗性免疫调节剂,将针对稳定性进行优化, 性能我们的IFx-Hu 2家族包含质粒DNA(pDNA)原料药,其可通过以下方法生产: 只需要目前免疫疗法成本的一小部分。pDNA编码复合细菌抗原Emm 55。 当在肿瘤细胞表面表达时,Emm 55吸引抗原呈递细胞和先天性巨噬细胞的其他细胞。 免疫反应非自身表位如肿瘤和HPV抗原然后以这样的方式暴露, 多抗原细胞和体液适应性免疫反应。基于Emm 55的疗法诱导 个性化,多价,全身性和持续的免疫反应,并有可能治疗 通过增强的肿瘤识别、免疫激活和表位扩散来治疗广泛的癌症。 在多项动物研究中,病灶内注射IFx-Hu 2.0具有已确立的安全性特征, 在皮肤黑色素瘤、默克尔细胞癌和皮肤癌的1期人体临床试验中进行测试。 鳞状细胞癌我们的初步临床数据证实了临床前的观察结果,显示 激活T细胞和B细胞免疫应答并减少肿瘤,无短期或长期不良反应。 我们建议使用已建立的方法优化IFx-Hu 2.1制剂的温度稳定性, 模型体外评价,包括标准质量控制方法和人阴道上皮 癌模型,随后在小鼠中进行体内摄取、表达和疾病进展研究 子宫颈癌的模型。室温储存和自我管理将避免繁琐的诊所访问, 改善预后和保持生育能力。IFx-Hu 2.1乳膏制剂将提供无毒的癌症 治疗性治疗,支持性护理要求最低,具有独特的交付, 适用性/对服务不足人群的影响。通过完成这些研究获得的数据将定位 Morphogenesis,Inc.提交一份研究性新药申请,以便在一个 当地社区医院(低资源环境)和南非(LMIC)。这些试验将是 SBIR第二阶段提案。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael J Shamblott其他文献

Michael J Shamblott的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael J Shamblott', 18)}}的其他基金

GENES AND GENE TARGETS FROM THE DOWN SYNDROME REGION
唐氏综合症区域的基因和基因靶点
  • 批准号:
    2655096
  • 财政年份:
    1998
  • 资助金额:
    $ 40万
  • 项目类别:
GENES AND GENE TARGETS FROM THE DOWN SYNDROME REGION
唐氏综合症区域的基因和基因靶点
  • 批准号:
    2332229
  • 财政年份:
    1997
  • 资助金额:
    $ 40万
  • 项目类别:
GENES AND GENE TARGETS FROM THE DOWN SYNDROME REGION
唐氏综合症区域的基因和基因靶点
  • 批准号:
    2196531
  • 财政年份:
    1996
  • 资助金额:
    $ 40万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 40万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了